Long-term secondary analysis of a phase II trial in 121 patients with resected high-risk melanoma given a 12-peptide vaccine: GM-CSF adjuvant did not change RFS or OS; two-site vs one-site vaccination improved RFS (HR 0.59), with a non-significant OS trend (HR 0.64).
Secondary analysisn = 121
Ninmer et al. Impact of GM-CSF and Two-Site Vaccination on Clinical Outcomes after Multipeptide Vaccination for Melanoma: Long-term Analysis of a Randomized Phase II Trial